Latest Innovation News

CAR Group Limited reported a 14% increase in net profit after tax to AUD 332.4 million for FY26, driven by strong revenue growth and AI innovation across its global vehicle marketplaces.

Elixinol Wellness (ASX: EXL) has posted a record quarterly revenue of A$4.3 million alongside a 45% gross margin, marking a clear shift from its US CBD origins to a diversified Australian wellness platform. Cost reductions and disciplined cash flow management underpin the company’s readiness to scale.

RocketDNA Ltd has secured a $1 million contract extension from BHP Mitsubishi Alliance to continue its autonomous drone operations in the Bowen Basin until October 2026, reinforcing its position in mining tech.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

James Hardie Industries posted a 64% jump in Q1 FY27 net sales to $1.475 billion, powered by the AZEK acquisition and solid organic growth. The company exceeded EBITDA guidance and raised its full-year outlook, targeting robust sales and cash flow growth amid cautious housing market assumptions.

Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.

Integral Diagnostics has installed Jason Martinez as its new CEO, marking a leadership change as the company prepares to present its FY26 results. Martinez brings over 20 years of diagnostic imaging experience and aims to drive growth and innovation following the retirement of long-serving CEO Ian Kadish.

Aura Consolidated Group delivers strong pro forma Q2 2026 results with 27% revenue growth and a 51% improvement in adjusted EBITDA following its acquisition of Qoria.

Block, Inc. delivered a robust Q2 2026 with 25% gross profit growth, driven by strong Cash App and Square performances, and raised its full-year guidance reflecting accelerating AI integration and hardware innovation.

REA Group Ltd (ASX:REA) posted a robust FY26 with revenue up 7% to A$1.793 billion and core net profit rising 15% to A$682 million, supported by record audience engagement and strategic AI investments.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

Ionic Rare Earths (ASX: IXR) has secured $8 million through a placement to back its Belfast Plant commercialisation and US growth plans, supported by a mix of domestic and international investors including a strategic US partner.